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ABSTRACT
Michalickova, DM, Kostic-Vucicevic, MM, Vukasinovic-Vesic,
MD, Stojmenovic, TB, Dikic, NV, Andjelkovic, MS, Djordjevic,
BI, Tanaskovic, BP, and Minic, RD. Lactobacillus helveticus Lafti
L10 supplementation modulates mucosal and humoral immunity
in elite athletes: a randomized, double-blind, placebo-controlled
trial. J Strength Cond Res 31(1): 62–70, 2017—To test the
influence of probiotic supplementation on humoral immune
response, a double-blind, placebo-controlled trial was con-
ducted. Thirty athletes (24 males and 6 females, females:
V_ O2max 38.2 6 4.9 ml$kg21$min21, age 23.2 6 1.4 years;
males: V_ O2max 57.5 6 9.2 ml$kg21$min21, age 24.0 6 2.4
years, mean 6 SD) were randomized either to the probiotic
group (Lactobacillus helveticus Lafti L10, 2 3 1010 colony-
forming units) or to the placebo group. Serum and saliva sam-
ples were collected at the baseline and after 14 weeks. Total
and specific antibacterial antibody levels of IgM, IgG, and IgA
classes were determined for different bacteria in the serum, and
in saliva, total and specific antibacterial IgA levels were exam-
ined. Total IgM was elevated in both probiotic (18%, 15–20%;
mean, 90% confidence interval; p = 0.02) and placebo group
(35%, 22–47%; p = 0.02), without observed differences in
changes between the groups. No significant changes in IgM
levels specific for tested bacteria were found. Total IgG level
was constant in both groups. A significant (16%, 22.8 to
35%, p = 0.04) reduction of anti–Enterococcus faecalis IgG
was noted in the placebo group, in comparison with the pro-
biotic group. There was a substantial decrease in total IgA level
in the placebo group, when measured either in serum (15%, 12–
18%, p = 0.04) or in saliva (35%, 21.4 to 53%, p = 0.03).
Significantly reduced levels of serum anti–lactic acid bacteria
IgA antibodies in the placebo group compared with the probiotic
group were detected for Lactobacillus rhamnosus LA68 (24%,
5.8–42%, p = 0.02) and for L. rhamnosus LB64 (15%, 2.7–
27%, p = 0.02). Probiotic administration could have beneficial
effects on systemic humoral and mucosal immune responses.




ecause of the competitive nature of professional
sports, elite athletes are constantly in need to push
boundaries, which is a difficult task, especially in
times of rapidly increasing global population.
Strenuous exercise leads to physical stress, which has an
impact on the individuals’ immune system. Although mod-
erate exercise has a beneficial effect on the immune system,
compared with a sedentary lifestyle, excessive amounts of
prolonged high-intensity exercise can impair immune func-
tion, leading to higher risk of upper respiratory tract infections
(URTI) (37). Upper respiratory tract infection occurs in the
period of strenuous exercise, particularly during winter
months (18), thus negatively influencing athletes’ training
and consequently impairing performance during competitions.
Mucosal immunity impairment has been suggested to be
a key risk factor for higher URTI incidence in elite athletes
(37). Secretory IgA is reported to play a multifunctional role
in mucosal immunity, including host protection by neutral-
izing bacterial, viral, and fungal antigens and modulation of
epithelial cells (9,21). It is generally considered that salivary
IgA level decreases in response to high-intensity exercise,
especially if it lasts over longer periods of time (.6 months)
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(14). Nevertheless, certain discrete dietary changes could
compensate for the detrimental effects of strenuous exercise
on mucosal immunity (14). Recent studies suggested that pro-
biotic supplementation could help better mucosal immunity
maintenance, or even induce its enhancement (15,31,36,38).
As part of immune modulation because of the consump-
tion probiotics, systemic humoral immune responses could
be induced as well. Several studies confirmed that immuno-
globulins, main mediators of humoral immunity, were
influenced by oral probiotic administration (21,28,29,32). In
addition, enhancement of specific humoral response would
be of special interest for professional athletes in terms of
prevention of bacterial infections and minimization of their
detrimental impact on training and performance.
The probiotic strain Lactobacillus helveticus Lafti L10 was
previously reported to have inherent immunity-enhancing
properties and nonpathogenic nature in animal studies (30).
These data were corroborated with human trials: an enhance-
ment of antigen-stimulated interferon-g production after
a month of daily intake of L. helveticus Lafti L10 at a dose of
2 3 1010 colony-forming units (CFUs) was reported in
a cohort of fatigued athletes experiencing recurrent viral in-
fections (8). Moreover, supplementation with L. helveticus Lafti
L10 reduced the duration of URTI episodes and increased
CD4+/CD8+ (T helper/T suppressor) cells ratio in a cohort
of elite athletes (Marinkovic et al., submitted). Although there
is an emerging amount of evidence that probiotics could mod-
ulate mucosal immune system, data regarding the influence of
probiotics on professional athletes’ humoral immunity are
rather scarce. Therefore, the aim of this study was to test
the effects of L. helveticus Lafti L10 supplementation not only
on the total antibody levels but also on specific antibacterial
antibody levels in serum and saliva.
METHODS
Experimental Approach to the Problem
The study included a randomized, double-blind, placebo-
controlled parallel-groups design. The athletes were ran-
domly allocated to the probiotic (n = 15) or the placebo
group (n = 15), taking into account maximal aerobic capacity
(determined by cardiopulmonary testing). All the partici-
pants finished the study.
We have tested both serum and salivary antibody reac-
tivity for several species/strains of Lactobacillus, and 3 clinical
isolates—2 of gram-negative bacteria Escherichia coli and Pro-
teus mirabilis, and a gram-positive Enterococcus faecalis. More-
over, total salivary IgA and total IgA, IgG, and IgM
antibodies in serum were determined.
The supplementation started in the middle of January, in
winter, and lasted for 14 weeks. The experimental group
received the probiotic capsules of L. helveticus Lafti L10 (23
1010 CFUs) daily for 14 weeks. Each capsule contained 1 3
1010 CFUs of L. helveticus Lafti L10, so subjects were in-
structed to take 2 capsules per day. The control group
received 2 placebo capsules also daily, which were identical
in taste and appearance as probiotic capsules. The placebo
capsules contained 1% magnesium stearate and 99% malto-
dextrin, and the probiotic capsules contained 72.2% of the
bacterial mass, 26.7% maltodextrin, and 1% magnesium stea-
rate. Capsules were composed of hydroxypropylmethylcel-
lulose and covered by titanium dioxide (TiO2). Both
probiotic and placebo capsules were kept in a refrigerator
(2–88 C).
The athletes were asked to return the remaining capsules
when coming to the final testing after the intervention. The
researchers counted the remained capsules; the compliance
in the probiotic group was 95.2% and that in the placebo
group was 94.8% (p = 0.74).
Both athletes and the study team were blinded to the
intervention until the statistical analyses were finished.
Subjects
A total of 30 elite athletes were involved in the trial: 24 men
(V_ O2max ranged from 49.5 to 82.0 ml$kg21$min21) and 6
women (V_ O2max ranged from 45.0 to 57.0 ml$kg21$min21),
aged 18–28 years, nonsmokers, with training .11 h$wk21.
Professional athletes from several different sports (badminton,
triathlon, bicycling, athletics, karate, kayaking, and judo) par-
ticipated in the study. Exclusion
criteria were sensitivity to the
ingredients of probiotics and
the use of probiotics and anti-
biotics a month before the
beginning of the study, recent
surgical intervention, and/or
the presence of chronic diseases
(immune, neurological, renal,
pulmonary etc.).
Athletes were asked to take
capsules after breakfast to
ensure the compliance. Further-
more, subjects were required to
refrain from supplements that
are intended for promotion of
TABLE 1. Physical and anthropometric characteristics of the participants.*†
Probiotic Lafti L10 Placebo p
Number 15 15
Males/females 12/3 12/3
Age (y) 22.5 6 2.9 23.6 6 2.9 0.88
V_ O2max (ml$kg21$min21) 54.3 6 10.9 55.2 6 8.2 0.80
BMI 22.9 6 2.5 22.9 6 2.5 0.95
Training loads (MET-hr$wk21) 96 6 52 97 6 56 0.94
*BMI, body mass index; MET, metabolic equivalent.
†Results are expressed as mean 6 SD.
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immune system (e.g.,): Echinacea, caffeine, Ginseng panax,
propolis, multivitamins, and multiminerals. Moreover, the par-
ticipants were asked to hold a steady training regimen and
adhere to a diet not containing yogurt and fermented milk
products.
All the experimental procedures in the current study
followed the guidelines laid down in Declaration of
Helsinki. The study was approved by the Ethics Commit-
tee of Sports Medicine Association of Serbia. Subjects were
informed of the benefits and risks of the investigation
before signing an informed consent approved by the
committee.
Procedures
Training Loads and Maximal Aerobic Capacity Determination.
Athletes were required to report their training loads
weekly, filling in the standard short form of International
Physical Activity Questionnaire (http://www.ipaq.ki.se/
downloads.htm). Training loads in metabolic equivalents
(MET-hr$wk21) were counted on the basis of completed
questionnaires, according to Ainsworth (1). Maximum
oxygen consumption was determined by a graded cardio-
pulmonary test on a treadmill
(Quark b2; Cosmed, Pavona,
Italy). The exercise intensity
was progressively increased,
and oxygen and CO2 concen-
tration of the inhaled and
exhaled air were measured. A
test was considered maximal if
the participants achieved 90%
or more of predicted maximal
heart rate for age and gender,
a plateau in oxygen consump-
tion was reached despite
increased workload, a respira-
tory exchange ratio was
greater than 1.00, and subjects
reached volitional exhaustion.
The training loads (MET-
hr$wk21) did not differ between the groups (Table 1). Max-
imal aerobic capacity did not change during the study (data
not shown).
Serum and Saliva Samples Collection. Samples were collected
before the cardiopulmonary testing. Blood samples (10 ml
per serum tube) were taken out of the antecubital vein.
Whole, unstimulated saliva was collected in a glass tube
for 2 minutes, after sitting quietly for a few minutes,
leaning forward, with their heads tilted (4). All the sam-
ples were collected twice: before the study and after the
study, at the same time (between 9:30 and 10:30 AM), to
avoid diurnal changes. Serum and saliva were separated
by centrifugation 31500 g, 15 minutes and 33000 g,
10 minutes, respectively, and stored frozen at 2208
C until analysis.
Total Salivary IgA Determination. Saliva samples were diluted
31000 and then analyzed for IgA concentrations using
a commercial enzyme-linked immunosorbent assay (IBL,
Hamburg, Germany). Samples were determined in dupli-
cates; the intra-assay coefficient of variation was 10%.
Figure 1. Levels of total salivary IgA in the probiotic and placebo groups at the baseline and after 14 weeks of
supplementation. Results are expressed as mean and SD. *p # 0.05.
Figure 2. Total serum antibodies: (A) IgG, (B) IgA, and (C) IgM antibody levels in the probiotic and placebo groups at the baseline and after 14 weeks of
supplementation. Results are expressed as mean 6 SD. *p # 0.05.
Lafti L10 modulates immunity in athletes
64 Journal of Strength and Conditioning Research
the TM
Copyright © National Strength and Conditioning Association Unauthorized reproduction of this article is prohibited.
Salivary flow (ml$min21) was determined by conversion of
the amount of saliva in grams to milliliters, assuming that
saliva density is 1 mg$ml21, and division by time of collection
(2 minutes). Salivary IgA antibody (sIgA) secretion rate
(mg$min21) was obtained by multiplying the absolute sIgA
concentration (mg$ml21) with saliva flow rate (ml$min21)
(4). Salivary protein concentration was determined by the
Lowry method (24).
Total Serum Antibody Assessment. Frozen serum samples were
sent to a certified human diagnostics laboratory (Laborator-
ija Beograd, Belgrade, Serbia) and immunoturbidimetric
method (Roshe Hitachi, Rotkreuz, Switzerland) was used
for the quantification of total IgA, IgG, and IgM in serum
samples.
Bacterial Strains and Growth Conditions. In this study, several
Lactobacillus species were used, such as L. helveticus Lafti L10
(Lallemand Health Solutions, Montreal, Canada), Lactobacillus
plantarum WCFS1 (Wageningen Centre for Food Sciences,
Wageningen, The Netherlands), Lactobacillus rhamnosus
LA68, L. rhamnosus LB64 (Institute of Virology, Vaccines
and Sera, Torlak), and Lactobacillus acidophilus ViVag (Phar-
ma Vinci A/S, Denmark); all the strains were grown in MRS
(deMan, Rogosa and Sharpe) medium (Institute of Virology,
Vaccines and Sera, “Torlak,” Belgrade, Serbia), without
shaking, at 378 C. Overnight cultures were centrifuged at
33000 g for 10 minutes at room temperature (RT), washed
twice with phosphate-buffered saline (PBS) and counted
using a hemocytometer. After the optical density of 1 3
108 of L. helveticus Lafti L10 was determined, all other
bacteria were diluted to the same optical density. Clinical
isolates of E. coli, P. mirabilis, and Enterococcus faecalis were
grown in Nutrient broth (Institute of Virology, Vaccines and
Sera, “Torlak”), and overnight cultures were also diluted to
the same optical density. Before usage, all bacterial species
were frozen once at 2208 C.
Antibacterial enzyme-linked immunosorbent assay. Antibacterial
enzyme-linked immunosorbent assay (ELISA) was essen-
tially done as previously described (34) with minor modifi-
cations. MaxiSorp plates (Nunc A/S, Roskilde, Denmark)
were filled with 50 mL/well of bacterial suspension. The
plates were centrifuged at 31500g for 10 minutes, and the
supernatant liquid was decanted. The plates were left for 2
hours at 508 C to dry. The plates were blocked with 200 mL/
well in 2% bovine serum albumin/PBS at 378 C for 1 h and
washed 3 times with PBS, and sera was added at an appro-
priate dilution. For the analysis of bacteria-specific IgG and
IgM, the sera was diluted 3400, and for specific IgA, sera
was diluted 350. Salivary IgA specific for bacteria was deter-
mined at a 34 dilution. Sera or saliva was incubated for 2
hours at 378 C and washed with PBS, and the following
secondary antibodies were used: monoclonal antihuman
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TABLE 3. Specific serum IgM antibodies for lactic acid bacteria and pathogenic bacteria.*
Probiotic Lafti L10 Placebo
Mean difference
(90% CI) pBaseline 14 wk
Change score





0.54 6 0.22 0.49 6 0.20 211 (27.3 to 22.7) 0.58 6 0.26 0.56 6 0.26 217 (219 to 216) 26.8 (224 to 9.0) 0.41
Lactobacillus rhamnosus LB64 0.29 6 0.12 0.28 6 0.13 22.9 (26.6 to 0.80) 0.34 6 0.20 0.33 6 0.16 7.8 (3.7 to 12) 210 (237 to 16) 0.42
Lactobacillus rhamnosus LA68 0.29 6 0.12 0.26 6 0.14 213 (216 to 210) 0.33 6 0.21 0.30 6 0.16 23.9 (27.8 to
0.10)
29.4 (232 to 13) 0.40
Lactobacillus helveticus Lafti
L10
0.43 6 0.13 0.39 6 0.17 212 (215 to 29.4) 0.50 6 0.29 0.48 6 0.27 1.9 (22.3 to 6.0) 213 (237 to 10) 0.26
Escherichia coli 0.29 6 0.14 0.25 6 0.12 26.9 (211 to 22.5) 0.31 6 0.18 0.31 6 0.16 3.1 (21.3 to 7.5) 29.7 (237 to 17) 0.46
Proteus mirabilis 0.46 6 0.16 0.46 6 0.12 21.6 (25.8 to 2.6) 0.55 6 0.27 0.54 6 0.28 21.9 (25.5 to 1.6) 0.4 (224 to 25) 0.97
Enterococcus faecalis 0.49 6 0.16 0.44 6 0.12 26.5 (210 to 22.6) 0.56 6 0.30 0.54 6 0.29 25.3 (28.1 to 22.5) 21.2 (222 to 20) 0.91
*Results are expressed as mean 6 SD. Change scores in the groups and mean difference in the change scores between the groups are expressed in percent.CI, confidence
interval.
TABLE 4. Specific serum IgA antibodies for lactic acid bacteria and pathogenic bacteria.*
Probiotic Lafti L10 Placebo
Mean difference
(90% CI) pBaseline 14 wk
Change score





0.16 6 0.09 0.15 6 0.09 23.6 (26.6 to 0.62) 0.17 6 0.07 0.15 6 0.06 29.8 (212 to 27.2) 6.2 (211 to 8.5) 0.47
Lactobacillus rhamnosus
LB64
0.12 6 0.05 0.11 6 0.05 22.8 (25.3 to 20.33) 0.17 6 0.11 0.14 6 0.09 217 (219 to 216) 15 (2.7 to 27) 0.02
Lactobacillus rhamnosus
LA68
0.09 6 0.06 0.08 6 0.05 24.3 (27.6 to 21.1) 0.11 6 0.07 0.08 6 0.07 228 (231 to 226) 24 (5.8 to 42) 0.02
Lactobacillus helveticus
Lafti L10
0.21 6 0.08 0.18 6 0.08 211 (214 to 27.4) 0.21 6 0.06 0.18 6 0.06 210 (213 to 28.4) 20.26 (218 to 18) 0.98
Escherichia coli 0.12 6 0.11 0.09 6 0.09 211 (215 to 27.6) 0.08 6 0.04 0.07 6 0.04 1.8 (22.8 to 6.6) 213 (240 to 14) 0.33
Proteus mirabilis 0.14 6 0.08 0.14 6 0.08 24.6 (26.4 to 22.5) 0.14 6 0.05 0.13 6 0.05 25.1 (27.9 to 22.3) 0.5 (16.8 to 17.8) 0.95
Enterococcus faecalis 0.16 6 0.07 0.15 6 0.08 25.8 (28.1 to 23.5) 0.19 6 0.10 0.17 6 0.08 23.2 (25.6 to 20.82) 22.6 (218 to 13) 0.73
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antihuman IgM (m-chain specific) biotin conjugate, 2500
times diluted, antihuman IgA (a-chain specific), 2000 times
diluted; all were obtained from Sigma Aldrich (St. Louis,
MO, USA). All secondary antibodies were incubated for 1
hour at RT. After washing with PBS, streptavidin–horse rad-
ish peroxidase (Biolegend, San Diego, CA, USA) diluted
2000 times was added and incubated for 1 hour at RT. Col-
ored substrate used was SigmaFast OPD (Sigma Aldrich),
and the reaction was developed for 10 minutes. The absor-
bance was read at 492 nm and at 620 nm and the latter was
subtracted from the former. Each sample was done in dupli-
cate, and intra-assay coefficients of variation were below or
equal to 10% for all the bacterial ELISAs performed.
Statistical Analyses
All statistical analyses were performed with GraphPad Prism
software. The normality of the data was checked by Wilk-
Shapiro test. The differences in the change scores between
the groups were assessed by an unpaired T-test. Spearman
correlation was used for checking the correlation between
different antibody subclasses. The results are expressed as
mean value and SD. P # 0.05 was considered significant.
RESULTS
Total Salivary IgA Level
There was a significant (35%, 21.4 to 53%; mean, 90% confi-
dence interval; p = 0.03) reduction in total salivary IgA
concentration in the placebo group (228%, 238 to 220%,
p = 0.02) in comparison with the probiotic group (28.7%,
215 to 1.7%, p = 0.34), Figure 1. No significant changes were
observed for protein concentration (1.5%,24.7 to 10%, p= 0.85),
salivary flow (29.2%, 299 to 76%, p = 0.80), and salivary IgA
secretion rate (3.5%, 225 to 34%, p = 0.65) between the groups.
Analysis of Total IgG, IgA, and IgM Antibody Levels in Serum
Mean difference between change scores in the groups was
not significant for total IgG (0.09%, 210 to 5.0%, p = 0.99)
and IgM level (227%, 268 to 215%, p = 0.14), as shown in
Figures 2A and 2C. However, the level of total IgM
increased in both the probiotic (18% [15–20%], p = 0.02)
and placebo groups (35%, 22–47%, p = 0.02). On the other
hand, there was a significant (15%, 12–18%, p = 0.04)
decrease in total IgA level in the placebo group (28.0%,
210 to 22.2%, p = 0.03), when compared with the probiotic
group (0.48%, 20.45 to 1.4%, p = 0.77) (Figure 2B).
Analysis of Specific Antibacterial Serum IgG Levels
The levels of serum IgG specific for different lactic acid
bacteria (LAB) species and for selected pathogenic bacteria
are shown in Table 2. Statistical analysis showed no differ-
ence in the groups for any of the LAB species used. A sig-
nificant 16% (22.8 to 35%, p = 0.04) reduction over the
course of study was noted for anti–E. faecalis IgG; it
decreased insignificantly by 2.0% (24.4 to 10%, p = 0.88)
in the probiotic group, but decreased significantly in the
placebo group by 10% (225 to 28.5%, p = 0.02).
Analysis of Specific Antibacterial Serum IgM Levels
No significant differences in reactivity for LAB species were
detected between the groups. This was also the case with
clinical isolates of pathogenic bacteria (Table 3).
Analysis of Specific Antibacterial Serum IgA Levels
No significant differences were detected between the indi-
vidual groups of sera, but statistically significant changes
with time were detected in the placebo group (Table 4). The
reduced levels of anti-LAB antibodies in the placebo group
in comparison with the probiotic group were detected for L.
rhamnosus LA68 at 24% (5.8–42%, p = 0.02) and for L. rham-
nosus LB64 at 15% (2.7–27%, p = 0.02). In the case of clinical
isolates of pathogenic bacteria, no differences in antibody
levels were detected in different time points.
Lactobacillus-Specific Salivary IgA
No statistically significant differences were observed in the
specific IgA level antibodies for any of the tested LAB
species between the groups (Figure 3).
DISCUSSION
The most important finding of this study was preservation of
total salivary IgA level in the group supplemented with Lafti
L10. Given the fact that mucosal surface is the first line of
defense against different pathogens, this finding might have
a practical application in terms of prevention of URTIs
during strenuous exercise in elite athletes. Our result is in
Figure 3. Specific salivary IgA antibodies: (A) anti–Lactobacillus plantarumWCFS1 (B) anti–Lactobacillus rhamnosus LA68, (C) anti–Lactobacillus helveticus
L10, and (D) anti–L. acidophilus Vivag antibody levels in the probiotic and placebo groups at the baseline and after 14 weeks of supplementation. Results are
expressed as mean 6 SD.
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accordance with literature data concerning highly active
individuals (15,36) and other immunologically susceptible
populations, such as the elderly and children (31,38). How-
ever, there are some studies showing a lack of positive
impact on mucosal immunity (10,16). This fact is of no sur-
prise because the effects of probiotics are strongly dose and
strain dependent.
In line with salivary IgA level maintenance, a trend of
systemic IgA level preservation occurred. However, we
cannot be sure that there is a direct connection between
these 2 findings because the production of secretory and
serum IgA are regulated differently and located in different
compartments. Consequently, the mechanisms by which
mucosal and humoral immunological responses could be
influenced by probiotic consumption are probably different
(11,23). Namely, the majority of adult human plasma cells
produce IgA antibodies (22,33), which exists as 2 subclasses,
IgA1 and IgA2. The former, predominant in the human
serum, is generated by B cells in the bone marrow and
peripheral lymphoid organs (11,23). On the other hand,
IgA2 is predominant in mucosal secretions (26) and is pro-
duced partly by B1 peritoneal cells (25%) and partly by B2
cells from mucosal associated lymphoid tissues (25).
Even though all individuals who participated in the study
are young adults and elite athletes, individual differences, as
in any other human population are vast, and this is also the
case for levels of specific antibacterial antibodies. Apart from
the diversity of each individual’s genetic background, there
are also differences in the histories of antigen encounter,
which ultimately shape antibody repertoire. An interesting
finding was that although serum IgA levels specific for
L. rhamnosus LA68 and L. rhamnosus LB64 were reduced
in the control group, salivary IgA was not lowered in any
of the LAB species tested. Yet, the analysis of IgA levels
specific for LAB either in saliva or serum showed no differ-
ence in the probiotic group. Moreover, the reduction in spe-
cific anti-LAB IgA levels might be explained by a certain
level of cross-reactivity between LAB species because all
the participants were told to restrain from fermented milk
products and other probiotic supplements. Therefore, the
consumption of Lactobacilli results in the maintenance of
certain anti-Lactobacillus IgA antibody levels, which is a rela-
tively specific effect, as we did not observe the change in the
antibody levels specific for other bacteria tested. Finally, it
might be concluded that specific salivary IgA is just a poor
indicator of specific intestinal IgA response, as reported by
previous studies (13,29).
Nevertheless, the mechanism by which probiotics
could induce salivary IgA remains elusive, because the
sIgA-mediated immunity is very complex. Some new
findings suggest that the generation of mucosal IgA+ B-cells
is both T-cell dependent and T-cell independent, but their
relative contributions are still unclear (6). Mucosal IgA+ cells
migrate out of the gut mucosa to the circulation, arriving at
the local mucosal immune tissues, such as the salivary
glands. There they produce IgA, secreted into the salivary
gland duct as sIgA (7,21,35).
IgM antibody class is the first immunoglobulin in serum to
elevate in concentration, generally within 1–2 weeks (28). It
is the most cross-reactive antibody class, as it represents the
first line of defense against pathogens. No changes in the
levels of antibacterial specific IgM levels were found, which
was to be expected because of the low IgM specificity.
Interestingly, total IgM antibody levels were significantly
increased in both probiotic and placebo groups. Previous
studies about the effects of exercise reported that the greatest
effect of acute exercise on humoral response was an increase
in serum IgM levels (27), although other authors reported no
change (17) or even a decrease (19). Different mechanisms
were proposed to explain this increase in IgM, including the
nonspecific interaction between sympathetic neural system
and immunity and antigen stimulation by larger amounts of
microorganisms entering the body during the intensive train-
ing (27). In addition, the observed reduction of IgA and an
increase of IgM, which was observed in the placebo group, is
also found in IgA-deficient individuals, where the lack of IgA
is compensated by the increase of IgM (5).
On the other hand, the IgG antibody class is considered to
be a true and main indicator of antigen encounter. It is the
most specific antibody class and provides immune memory
(28). A significant 16% reduction during the study was noted
for anti–E. faecalis IgG. It seems that supplementation with
Lafti L10 helped in maintaining adequate antigen-specific
response against a gram-positive uropathogenic strain ofE. fae-
calis, but not against gram-negative Proteus mirabilis or E. coli.
These findings indicate that supplementation with Lafti can
enhance specific but not generalized immune activation.
Therefore, a future study should include testing of specific
responses to a greater number of antigens, especially those
of common infective agents causing URTI, such as influenza.
Several trials conducted in athletes showed the ability of
some strains to reduce the incidence of URTIs (10), the
severity of symptoms (39), and shorten the duration of an
URTI episode (40). Lafti showed the potential to reduce the
duration of an URTI episode and decrease the number of
respiratory symptoms (Marinkovic et al., submitted).
Similar enhancement of specific humoral response were
observed against Haemophilus influenza (32), Cholera (29),
and enterotoxigenic E. coli (28). However, to our knowledge,
this is the first study to examine specific humoral responses
upon probiotic supplementation in professional athletes.
Apparently, circulating sera IgG is critical for defense
against URTI (12,20), but there are some contrasting findings
concerning its response to prolonged exercise (37). It is re-
ported that serum levels of both total IgG and IgG subclasses
are significantly lower in swimmers in comparison with sed-
entary controls (27). However, total IgG did not change dur-
ing the period of supplementation in both probiotic and
placebo groups. Similar results were reported by Gleeson
(15). In fact, this could be expected, because total levels of
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immunoglobulins are less likely to respond to dietary changes,
except in some extremes (HIV infections, severe malnutrition)
(3). Conversely, there are studies showing that probiotics
might affect circulating antibody counts: probiotic supple-
mentation of critically ill patients resulted in a substantial
increase of systemic IgA or IgG concentrations (2,38).
Correlation found for IgG, IgM, and IgA levels in different
individuals was trivial, which is also in connection with the
specificity of these different antibody classes.
In conclusion, we suggest that L. helveticus Lafti L10 sup-
plementation could be an appropriate dietary aid in humoral
and mucosal immunity maintenance, which is critical for
URTI prevention in elite athletes. Further investigations
should elucidate the mechanisms of the interactions between
L. helveticus and immunity.
PRACTICAL APPLICATIONS
The current study indicates that probiotic supplementation
restores mucosal and humoral immunity impairment caused
by intense training during winter months. Apparently,
respiratory illness occurs typically in the period of heavy
exercise, particularly during winter months (18). In that
manner, every training disruption during preparations for
forthcoming sport competitions may result in performance
impairment. In addition, humoral and especially mucosal
immunity plays a crucial role in the defense against pathogen
translocation. Hence, our findings might have a practical
implication, in the sense of prevention, or the reduction of
length and severity of URTI episodes. Additionally, athletes
and their coaches might take L. helveticus Lafti L10 into
consideration as an appropriate nutritional supplement, to
avoid performance impairment because of illness.
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